Avalon Trust Co Has $24.89 Million Position in VanEck Pharmaceutical ETF $PPH

Avalon Trust Co lessened its holdings in shares of VanEck Pharmaceutical ETF (NASDAQ:PPH) by 1.8% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 275,400 shares of the company’s stock after selling 5,077 shares during the quarter. VanEck Pharmaceutical ETF makes up approximately 1.6% of Avalon Trust Co’s portfolio, making the stock its 18th largest holding. Avalon Trust Co owned 2.22% of VanEck Pharmaceutical ETF worth $24,885,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. Citigroup Inc. raised its holdings in shares of VanEck Pharmaceutical ETF by 987.8% during the 3rd quarter. Citigroup Inc. now owns 718,199 shares of the company’s stock valued at $64,896,000 after purchasing an additional 652,175 shares in the last quarter. Clal Insurance Enterprises Holdings Ltd acquired a new position in VanEck Pharmaceutical ETF during the second quarter worth $28,587,000. JPMorgan Chase & Co. increased its position in VanEck Pharmaceutical ETF by 2,852.2% during the second quarter. JPMorgan Chase & Co. now owns 255,837 shares of the company’s stock worth $22,503,000 after buying an additional 247,171 shares during the last quarter. Verity & Verity LLC bought a new position in VanEck Pharmaceutical ETF during the second quarter valued at about $11,551,000. Finally, Tower Research Capital LLC TRC lifted its position in shares of VanEck Pharmaceutical ETF by 346,140.0% in the second quarter. Tower Research Capital LLC TRC now owns 34,624 shares of the company’s stock worth $3,046,000 after buying an additional 34,614 shares during the last quarter.

VanEck Pharmaceutical ETF Stock Performance

Shares of NASDAQ PPH opened at $110.38 on Monday. The firm has a market cap of $1.22 billion, a price-to-earnings ratio of 20.21 and a beta of 0.54. The business’s 50-day simple moving average is $106.15 and its 200-day simple moving average is $97.38. VanEck Pharmaceutical ETF has a 52 week low of $77.67 and a 52 week high of $112.58.

VanEck Pharmaceutical ETF Cuts Dividend

The business also recently announced a quarterly dividend, which was paid on Wednesday, December 31st. Shareholders of record on Monday, December 29th were given a dividend of $0.3106 per share. The ex-dividend date of this dividend was Monday, December 29th. This represents a $1.24 dividend on an annualized basis and a yield of 1.1%.

VanEck Pharmaceutical ETF Profile

The VanEck Pharmaceutical ETF (PPH) is an exchange-traded fund that is based on the MVIS US Listed Pharmaceutical 25 index, a market-cap-weighted index of 25 of the largest global pharmaceutical firms. PPH was launched on Feb 1, 2000 and is managed by VanEck.